嗯你这个数据是对的。ABBV给的BTK今年指引是继续大幅度下跌，2.9B了。。2023年都还有3.6B。In oncology, we expect sales of $5.7 billion, including Imbruvica revenue of $2.9 billion and Venclexta sales of $2.4 billion.